Pancreatic Cancer Research

ResearcherAbramson Cancer CenterActive in the last 2 years

Mark H. O’Hara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2751-6122; OpenAlex author ID A5042029338. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 2, last author 3)
Trials
4 (principal investigator on 3)
Grants
1
Labs led
1
Collaborators
121
Papers, trials and grants by year

2017: 1 paper, 1 trial · 2018: 1 paper, 1 trial · 2019: 2 papers · 2020: 3 papers · 2021: 5 papers · 2022: 4 papers, 1 trial · 2023: 2 papers, 1 trial · 2024: 3 papers · 2025: 2 papers · 2026: 4 papers, 1 grant

Papers 27

  1. Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Tria… Co-author DOI 10.1001/jamaoncol.2026.0870↗
  2. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  3. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  4. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
  5. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Co-author DOI 10.1002/cncr.35936↗
  6. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Last author DOI 10.1016/j.xcrm.2025.102301↗
  7. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  8. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  9. KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma. First author DOI 10.1158/1535-7163.mct-23-0519↗
  10. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Co-author DOI 10.1158/1078-0432.ccr-23-1467↗
  11. Advancements in Systemic Therapy for Pancreatic Cancer. Last author DOI 10.1200/edbk_397082↗
  12. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Co-author DOI 10.1016/s1470-2045(22)00369-2↗
  13. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗
  14. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.22.00060↗
  15. Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28127↗
  16. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  17. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000854↗
  18. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  19. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Co-author DOI 10.1200/jco.21.00003↗
  20. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28099↗
  21. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Last author DOI 10.1016/j.ccell.2020.08.004↗
  22. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.07.017↗
  23. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adeno… Co-author DOI 10.1158/1078-0432.ccr-19-3313↗
  24. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. First author DOI 10.1001/jamaoncol.2019.0684↗
  25. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. Co-author DOI 10.1200/po.18.00271↗
  26. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
  27. Combining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes. Co-author DOI 10.1021/acsnano.7b05503↗

Trials 4

  1. Collection of Circulating Biomarkers in Pancreatic Cancer Principal investigator NCT05743049↗
  2. A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Study chair NCT05484011↗
  3. DC Vaccine in Pancreatic Cancer Principal investigator NCT03592888↗
  4. CAR T Cell Immunotherapy for Pancreatic Cancer Principal investigator NCT03323944↗

Grants 1

  1. Clinical Accelerator Initiative grant: Mark O'Hara AWARD lustgarten:2026-mark-o-hara-clinical-accelerator-initiative-grant-ma

Closest collaborators

The 25 strongest of 121 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kim A. Reiss · 14 shared papers, 2018–2026 · strength 2.10
  2. Erica L. Carpenter · 11 shared papers, 2017–2026 · strength 1.44
  3. Robert H. Vonderheide · 9 shared papers, 2020–2026 · strength 1.30
  4. Jacob Edward Till · 9 shared papers, 2020–2026 · strength 1.18
  5. Thomas Benjamin Karasic · 7 shared papers, 2019–2025 · strength 0.94
  6. Peter James O'Dwyer · 7 shared papers, 2018–2024 · strength 0.74
  7. Zev A. Wainberg · 5 shared papers, 2021–2026 · strength 0.73
  8. Eileen Mary O'Reilly · 5 shared papers, 2021–2026 · strength 0.73
  9. Susan M. Domchek · 5 shared papers, 2019–2026 · strength 0.72
  10. Timothy J. Brown · 3 shared papers, 2023–2026 · strength 0.70
  11. Andrew H. Ko · 5 shared papers, 2020–2026 · strength 0.63
  12. Ben Z. Stanger · 4 shared papers, 2017–2024 · strength 0.59
  13. Katherine L. Nathanson · 4 shared papers, 2019–2026 · strength 0.59
  14. Charles M. Vollmer · 4 shared papers, 2018–2026 · strength 0.56
  15. Robert A. Wolff · 4 shared papers, 2021–2026 · strength 0.54
  16. George Albert Fisher · 4 shared papers, 2021–2026 · strength 0.54
  17. Lacey Padrón · 3 shared papers, 2022–2026 · strength 0.45
  18. Brian Matthew Wolpin · 3 shared papers, 2021–2026 · strength 0.43
  19. Jonathan Andrew Nowak · 3 shared papers, 2021–2026 · strength 0.43
  20. John Peter Plastaras · 3 shared papers, 2018–2025 · strength 0.37
  21. Edgar Ben‐Josef · 3 shared papers, 2018–2025 · strength 0.37
  22. James M. Metz · 3 shared papers, 2018–2025 · strength 0.37
  23. Zain M. Hannan · 2 shared papers, 2021–2026 · strength 0.34
  24. Bryson W. Katona · 3 shared papers, 2020–2022 · strength 0.34
  25. Samuele Cannas · 2 shared papers, 2024–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.